• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Design of Factor XIII V34X activation peptides to control ability to interact with thrombin mutants.用于控制与凝血酶突变体相互作用能力的凝血因子XIII V34X激活肽的设计
Biochim Biophys Acta. 2011 Dec;1814(12):1955-63. doi: 10.1016/j.bbapap.2011.07.012. Epub 2011 Jul 21.
2
Screening cleavage of Factor XIII V34X Activation Peptides by thrombin mutants: A strategy for controlling fibrin architecture.通过凝血酶突变体筛选因子 XIII V34X 激活肽的裂解:一种控制纤维蛋白结构的策略。
Biochim Biophys Acta Proteins Proteom. 2017 Oct;1865(10):1246-1254. doi: 10.1016/j.bbapap.2017.07.001. Epub 2017 Jul 4.
3
Probing thrombin's ability to accommodate a V34F substitution within the factor XIII activation peptide segment (28-41).探究凝血酶在因子XIII激活肽段(28 - 41)内接纳V34F替代的能力。
J Pept Res. 2004 Mar;63(3):241-52. doi: 10.1111/j.1399-3011.2004.00132.x.
4
Employing mutants to study thrombin residues responsible for factor XIII activation peptide recognition: a kinetic study.利用突变体研究凝血酶中负责因子XIII激活肽识别的残基:一项动力学研究。
Biochemistry. 2007 Mar 6;46(9):2444-52. doi: 10.1021/bi0622120. Epub 2007 Feb 8.
5
Thrombin activity is unaltered by N-terminal truncation of factor XIII activation peptides.凝血酶活性不会因因子 XIII 激活肽的 N 端截短而改变。
Biochemistry. 2004 Apr 13;43(14):4150-9. doi: 10.1021/bi049796v.
6
Thrombin hydrolysis of V29F and V34L mutants of factor XIII (28-41) reveals roles of the P(9) and P(4) positions in factor XIII activation.凝血酶对因子 XIII (28 - 41) 的V29F和V34L突变体的水解揭示了P(9)和P(4)位点在因子 XIII 激活中的作用。
Biochemistry. 2002 Feb 26;41(8):2859-68. doi: 10.1021/bi0157823.
7
Effects of introducing fibrinogen Aalpha character into the factor XIII activation peptide segment.引入纤维蛋白原 Aalpha 结构域至因子 XIII 激活肽片段的影响。
Biochemistry. 2010 Apr 6;49(13):2918-24. doi: 10.1021/bi902127u.
8
Modeling of factor XIII activation peptide (28-41) V34L mutant bound to thrombin.与凝血酶结合的因子XIII激活肽(28 - 41)V34L突变体的建模。
J Biomol Struct Dyn. 2008 Dec;26(3):387-94. doi: 10.1080/07391102.2008.10507253.
9
Cleavage of factor XIII by human neutrophil elastase results in a novel active truncated form of factor XIII A subunit.人中性粒细胞弹性蛋白酶对因子XIII的切割产生了一种新型的有活性的因子XIII A亚基截短形式。
Thromb Haemost. 2008 Apr;99(4):668-74. doi: 10.1160/TH07-09-0577.
10
Probing interactions between the coagulants thrombin, Factor XIII, and fibrin(ogen).探究凝血剂凝血酶、因子 XIII 和纤维蛋白(原)之间的相互作用。
Arch Biochem Biophys. 2006 Jan 1;445(1):36-45. doi: 10.1016/j.abb.2005.11.009. Epub 2005 Dec 1.

引用本文的文献

1
Screening cleavage of Factor XIII V34X Activation Peptides by thrombin mutants: A strategy for controlling fibrin architecture.通过凝血酶突变体筛选因子 XIII V34X 激活肽的裂解:一种控制纤维蛋白结构的策略。
Biochim Biophys Acta Proteins Proteom. 2017 Oct;1865(10):1246-1254. doi: 10.1016/j.bbapap.2017.07.001. Epub 2017 Jul 4.
2
Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation.补体系统 MASP-1 对凝血因子的激活和血浆血栓形成的影响。
PLoS One. 2012;7(4):e35690. doi: 10.1371/journal.pone.0035690. Epub 2012 Apr 20.

本文引用的文献

1
The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A.表达抗凝剂促凝血酶原突变体 W215A/E217A 的小鼠,其炎症性关节疾病的发展减弱。
Blood. 2011 Jun 9;117(23):6326-37. doi: 10.1182/blood-2010-08-304915. Epub 2011 Mar 24.
2
Molecular mechanisms affecting fibrin structure and stability.影响纤维蛋白结构和稳定性的分子机制。
Arterioscler Thromb Vasc Biol. 2011 Mar;31(3):494-9. doi: 10.1161/ATVBAHA.110.213389.
3
Ligand binding shuttles thrombin along a continuum of zymogen- and proteinase-like states.配体结合穿梭物沿着酶原和蛋白酶样状态的连续体推动凝血酶。
J Biol Chem. 2010 Sep 10;285(37):28651-8. doi: 10.1074/jbc.M110.154914. Epub 2010 Jul 16.
4
Engineering thrombin for selective specificity toward protein C and PAR1.工程化凝血酶以选择性识别蛋白 C 和 PAR1。
J Biol Chem. 2010 Jun 18;285(25):19145-52. doi: 10.1074/jbc.M110.119875. Epub 2010 Apr 19.
5
Crystal structure of thrombin bound to the uncleaved extracellular fragment of PAR1.凝血酶与 PAR1 未裂解的细胞外片段结合的晶体结构。
J Biol Chem. 2010 May 14;285(20):15393-15398. doi: 10.1074/jbc.M110.115337. Epub 2010 Mar 17.
6
Mechanism of the anticoagulant activity of thrombin mutant W215A/E217A.凝血酶突变体W215A/E217A抗凝活性的机制
J Biol Chem. 2009 Sep 4;284(36):24098-105. doi: 10.1074/jbc.M109.025403. Epub 2009 Jul 8.
7
Modeling of factor XIII activation peptide (28-41) V34L mutant bound to thrombin.与凝血酶结合的因子XIII激活肽(28 - 41)V34L突变体的建模。
J Biomol Struct Dyn. 2008 Dec;26(3):387-94. doi: 10.1080/07391102.2008.10507253.
8
The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis.血液凝固因子XIII在纤维蛋白溶解和血栓形成中的作用。
Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):190-205. doi: 10.2174/187152508784871990.
9
Thrombin.凝血酶
Mol Aspects Med. 2008 Aug;29(4):203-54. doi: 10.1016/j.mam.2008.01.001. Epub 2008 Feb 1.
10
Thrombin mutant W215A/E217A acts as a platelet GPIb antagonist.凝血酶突变体W215A/E217A可作为血小板糖蛋白Ib拮抗剂。
Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):329-34. doi: 10.1161/ATVBAHA.107.156273. Epub 2007 Oct 25.

用于控制与凝血酶突变体相互作用能力的凝血因子XIII V34X激活肽的设计

Design of Factor XIII V34X activation peptides to control ability to interact with thrombin mutants.

作者信息

Jadhav Madhavi A, Lucas R Cory, Goldsberry Whitney N, Maurer Muriel C

机构信息

Chemistry Department, University of Louisville, Louisville, KY, USA.

出版信息

Biochim Biophys Acta. 2011 Dec;1814(12):1955-63. doi: 10.1016/j.bbapap.2011.07.012. Epub 2011 Jul 21.

DOI:10.1016/j.bbapap.2011.07.012
PMID:21798378
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3645320/
Abstract

Thrombin helps to activate Factor XIII (FXIII) by hydrolyzing the R37-G38 peptide bond. The resultant transglutaminase introduces cross-links into the fibrin clot. With the development of therapeutic coagulation factors, there is a need to better understand interactions involving FXIII. Such knowledge will help predict ability to activate FXIII and thus ability to promote/hinder the generation of transglutaminase activity. Kinetic parameters have been determined for a series of thrombin species hydrolyzing the FXIII (28-41) V34X activation peptides (V34, V34L, V34F, and V34P). The V34P substitution introduces PAR4 character into the FXIII, and the V34F exhibits important similarities to the cardioprotective V34L. FXIII activation peptides containing V34, V34L, or V34P could each be accommodated by alanine mutants of thrombin lacking either the W60d or Y60a residue in the 60-insertion loop. By contrast, FXIII V34F AP could be cleaved by thrombin W60dA but not by Y60aA. FXIII V34P is highly reliant on the thrombin W215 platform for its strong substrate properties whereas FXIII V34F AP becomes the first segment that can maintain its K(m) upon loss of the critical thrombin W215 residue. Interestingly, FXIII V34F AP could also be readily accommodated by thrombin L99A and E217A. Hydrolysis of FXIII V34F AP by thrombin W217A/E217A (WE) was similar to that of FXIII V34L AP whereas WE could not effectively cleave FXIII V34P AP. FXIII V34F and V34P AP show promise for designing FXIII activation systems that are either tolerant of or greatly hindered by the presence of anticoagulant thrombins.

摘要

凝血酶通过水解R37 - G38肽键来帮助激活因子XIII(FXIII)。产生的转谷氨酰胺酶会在纤维蛋白凝块中引入交联。随着治疗性凝血因子的发展,需要更好地理解涉及FXIII的相互作用。此类知识将有助于预测激活FXIII的能力,进而预测促进/阻碍转谷氨酰胺酶活性产生的能力。已测定了一系列水解FXIII(28 - 41)V34X激活肽(V34、V34L、V34F和V34P)的凝血酶种类的动力学参数。V34P取代将PAR4特性引入FXIII,且V34F与具有心脏保护作用的V34L表现出重要的相似性。含有V34、V34L或V34P的FXIII激活肽均可被60插入环中缺乏W60d或Y$60a$残基的凝血酶丙氨酸突变体容纳。相比之下,FXIII V34F AP可被凝血酶W60dA切割,但不能被Y60aA切割。FXIII V34P因其强大的底物特性高度依赖凝血酶W215平台,而FXIII V34F AP成为在关键凝血酶W215残基缺失时仍能维持其K(m)的首个片段。有趣的是,FXIII V34F AP也可被凝血酶L99A和E217A轻易容纳。凝血酶W217A/E217A(WE)对FXIII V34F AP的水解与FXIII V34L AP相似,但WE不能有效切割FXIII V34P AP。FXIII V34F和V34P AP在设计对抗凝凝血酶的存在具有耐受性或受到极大阻碍的FXIII激活系统方面显示出前景。